- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 01.04. | AEON Biopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.04. | AEON Biopharma GAAP EPS of -$0.71 | 1 | Seeking Alpha | ||
| 29.03. | AEON Biopharma Announces Redemption of Public Warrants | 1 | GlobeNewswire (USA) | ||
| 29.03. | AEON Biopharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 29.03. | AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results | 52 | GlobeNewswire (Europe) | - Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine... ► Artikel lesen | |
| 29.03. | AEON Biopharma, Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 28.03. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | AEON Biopharma aligns with FDA on Phase 3 migraine trials | 1 | Investing.com | ||
| 19.03. | AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine | 30 | GlobeNewswire (Europe) | - FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine - - An interim analysis from the ongoing... ► Artikel lesen | |
| 19.03. | AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements | 202 | GlobeNewswire (Europe) | -- Termination of the Forward Purchase Agreements simplifies AEON's capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner... ► Artikel lesen | |
| 19.03. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.02. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.01. | US STOCKS United Airlines, AEON Biopharma, Plug Power | 62 | Reuters | ||
| 18.01. | AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference | 1 | GlobeNewswire (USA) | ||
| 23.11.23 | AEON Biopharma, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.11.23 | AEON Biopharma, Inc. GAAP EPS of -$0.04 | 2 | Seeking Alpha | ||
| 13.11.23 | AEON Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.23 | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,235 | +0,82 % | Evotec: War dieser Crash berechtigt? | Auf den ersten Blick wirkten die Ergebnisse des Vorjahres, die Evotec am Mittwochmorgen vorlegte, zwar nicht gerade gut, aber sie hätten nie und nimmer die Basis für einen Crash von 32 Prozent sein... ► Artikel lesen | |
| QIAGEN | 38,760 | +2,16 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 25,300 | +31,43 % | PEGY, CGEM and IFBD among mid-day movers | ||
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| CABALETTA BIO | 11,010 | -9,61 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,530 | +3,01 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,170 | -2,09 % | Should You Hold Immunovant (IMVT)? | ||
| KEROS THERAPEUTICS | 57,86 | +6,77 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 24,360 | +2,22 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,730 | +4,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| ARCELLX | 51,92 | +1,05 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| DAY ONE BIOPHARMACEUTICALS | 14,920 | +12,94 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| BIONTECH | 82,40 | +2,11 % | Besser als BioNTech oder Moderna? Diese Aktie schlägt den Markt seit Jahren - kann sie das wieder? | Sie ist etabliert, zahlt eine Dividende und liefert schon lange eine überdurchschnittliche Performance ab. Diese Biotech-Aktie sollten Anleger auf dem Schirm haben. Das US-Biotech-Unternehmen Amgen... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 33,370 | +0,06 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| NUVALENT | 66,86 | +1,20 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen |
Das Unternehmen AEON BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,940 Euro und damit +16,51 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
